Objective To analyze the correlation between changes in levels of basic fibroblast growth factor(bFGF), microribonucleic acid-1233(miR-1233), D-dimer(D-D), and fibrinogen(Fib) and the occurrence of pulmonary embolism in lung cancer patients. Methods One hundred and ten lung cancer patients with pulmonary embolism diagnosed in the Respiratory Department of North China University of Technology Affiliated Hospital from June 2018 to June 2021 were selected as the embolism group. In addition, 110 lung cancer patients who were admitted to the hospital during the same period but did not have pulmonary embolism were selected as the non-embolism group. The serum bFGF, miR-1233, plasma D-D, Fib levels, coagulation function indicators, comorbidities, lung cancer pathology indicators, and other related data of the two groups of patients were compared at admission; The value of receiver operating characteristic curve(ROC) analysis of bFGF, miR-1233, D-D, and Fib in predicting the occurrence of pulmonary embolism in patients; Logistic regression model was used to analyze the relationship between bFGF, miR-1233, D-D, Fib and the occurrence of pulmonary embolism in lung cancer patients. Results The levels of bFGF, miR-1233, D-D, and Fib in the embolization group were higher than those in the non-embolization group(t/P=4.749/<0.001, 9.244/<0.001, 16.846/<0.001, 9.389/<0.001); The PT, APTT, and INR measurements of patients in the embolization group were lower than those in the non-embolization group(t/P=8.131/<0.001, 7.875/<0.001, 6.379/<0.001); The areas under the ROC curve(AUC) predicted by bFGF, miR-1233, D-D, and Fib for pulmonary embolism in lung cancer patients were 0.687, 0.821, 0.947, and 0.766, respectively, with D-D having the highest AUC(Z/P=5.102/<0.001, 4.910/<0.001, 3.776/<0.001); Logistic regression model analysis showed that bFGF, miR-1233, D-D, and Fib were all elevated, Atrial fibrillation was an independent risk factor for pulmonary embolism in lung cancer patients [OR(95%CI)=1.486(1.059-2.086), 1.672(1.128-2.479), 2.018(1.246-3.268), 1.912(1.066-3.428), 2.164(1.298-3.609)],PT,APTT and INR were all elevated was an independent protective factors[OR(95%CI)=0.618(0.404-0.946), 0.640(0.428-0.956), 0.501(0.280-0.894)].Conclusion Elevated levels of serum bFGF, miR-1233, plasma D-D, and Fib can increase the risk of pulmonary embolism in lung cancer patients. Detecting these indicators, especially D-D levels, has important value in predicting the occurrence of pulmonary embolism in patients.

Objective To analyze the clinical value of splicing factor 3b subunit 4(SF3B4) and microRNA-96(miR-96) expression in gastric cancer disease and prognosis evaluation in endoscopic biopsy tissue. Methods Ninety-five gastric cancer patients diagnosed and treated in the General Surgery Department of Honghu People's Hospital in Hubei Province from January to December 2017 were selected as the gastric cancer group, and 60 patients with benign gastric diseases were selected as the non gastric cancer group. Real time fluorescence quantitative PCR(RT qPCR) was used to detect the expression of SF3B4 and miR-96 in tissues, and the differences in SF3B4 and miR-96 expression in different clinical and pathological data were compared; The value of using ROC curve analysis to predict poor 1-year prognosis of gastric cancer using SF3B4 and miR-96; Multivariate logistic regression analysis of risk factors for death in gastric cancer patients; Kaplan Meier method was used to analyze the relationship between SF3B4, miR-96 expression and survival. Results The expression of SF3B4 and miR-96 in tumor tissues of gastric cancer group was significantly higher than that in adjacent tissues and non gastric cancer group lesion tissues(F/P=516.766/<0.001, 887.495/<0.001). The expression of SF3B4 and miR-96 in patients with poorly differentiated gastric cancer, maximum tumor diameter ≥ 5 cm, T3-4, lymph node metastasis, and cTNM staging Ⅲ-Ⅳ was significantly higher than that in patients with moderately well differentiated gastric cancer, maximum tumor diameter<5 cm, T1-2 Patients with no lymph node metastasis and cTNM stage Ⅰ-Ⅱ(SF3B4: t/P=4.151/<0.001, 5.695/<0.001, 6.561/<0.001, 7.943/<0.001, 4.629/<0.001; miR-96: t/P=4.543/<0.001, 3.692/<0.001, 5.061/<0.001, 5.842/<0.001, 5.109/<0.001). The AUC of SF3B4, miR-96, and their combination for predicting poor 1-year prognosis in gastric cancer were 0.785, 0.779, and 0.952, respectively. The combined predictive efficacy of SF3B4, miR-96, and their combination was superior to their individual predictive efficacy(Z/P=3.451/0.017, 3.565/0.014). Multivariate logistic regression analysis showed that SF3B4 ≥ 1.51, miR-96 ≥ 1.28, poorly differentiated tumor, maximum tumor diameter ≥ 5 cm, depth of tumor infiltration T3-4, presence of lymph node metastasis, and cTNM stage Ⅲ-Ⅳ were independent risk factors for 1-year mortality in gastric cancer [OR(95%CI)=4.225(1.034-4.623), 3.877(1.142-6.189), 2.261(1.275-5.726), 2.487(1.338-7.516), 2.088(1.023-5.367) 2.779(1.161-4.591), 3.013(1.416-5.791)]. Among 95 gastric cancer patients, 36 survived and 59 died at the endpoint of follow-up. The median survival time of gastric cancer patients with SF3B4 ≥ 1.51 and miR-96 ≥ 1.28 was(23.7 ± 5.4) months lower than that of SF3B4<1.51 or miR-96<1.28 patients(31.2±6.5) months(Log rank=11.457, P<0.001). Conclusion The expression of SF3B4 and miR-96 in gastric cancer patients undergoing gastroscopy biopsy is significantly increased, which is closely related to the severity, prognosis, and survival of the disease. It can be used as a biomarker for evaluating the condition and prognosis of gastric cancer, and the combined detection of the two can improve the sensitivity and specificity of predicting poor prognosis of gastric cancer.

Objective To observe the effects of transcatheter arterial chemoembolization(TACE) combined with microwave ablation on serum tumor markers and T lymphocyte subsets in patients with primary hepatocellular carcinoma(HCC). Methods Collect clinical data of 104 patients with primary HCC admitted to the Interventional Department of Harbin Medical University Affiliated Cancer Hospital from October 2018 to December 2021. They were randomly divided into a TACE group of 52 cases(TACE treatment) and a combination group of 52 cases(TACE+microwave ablation treatment). Evaluate the efficacy one month after surgery, compare the liver function indicators, serum tumor markers, and T lymphocyte subsets of the two groups before and after treatment, and calculate the incidence of patient complications. Results The total effective rate of the combined group was 86.5%, higher than the 69.2% of the TACE group(χ2/P=4.522/0.033); After one month of treatment, the AST and ALT levels in the combination group were lower than those in the TACE group(t=10.473, 8.602, P<0.001); The AFP level in the combination group was lower than that in the TACE group(t=11.724, P<0.001); The CD4+and CD4+/CD8+in the combined group were higher than those in the TACE group, while CD8+was lower than those in the TACE group(t=3.913, 5.460, 5.586, all P<0.001); there="" was="" no="" statistically="" significant="" difference="" in="" the="" incidence="" of="" complications="" between="" two="" p="">0.05). Conclusion Primary HCC patients receiving TACE combined with microwave ablation treatment can significantly reduce their serum tumor marker levels, improve liver and immune function, and enhance overall efficacy.

Objective To study the correlation between miR-552, heat shock protein 90α(HSP90α) and clinicopathological factors and prognosis of laryngeal carcinoma. Methods From January 2014 to January 2017, 87 patients with laryngeal cancer from the Department of Otorhinolaryngology of Wuhan Third Hospital were selected as the LGC group, and 45 patients with benign laryngeal diseases were selected as the non-LGC group. The miR-552, HSP90αand clinical and pathological factors were compared between the two groups; Receiver operating characteristic(ROC) was used to analyze the efficacy of miR-552 and HSP90αin predicting the death of patients with laryngeal cancer; Multivariate Logistic regression analysis was used to analyze the risk factors of death in patients with laryngeal cancer. Kaplan-Meier analysis of the relationship between miR-552 and HSP90α and survival. Results LGC group patients miR-552 and HSP90 α The expression was significantly higher in non LGC patients(t/P=11.076/<0.001, 6.591/<0.001). MiR-552 and HSP90 in patients with poorly differentiated, maximum tumor diameter ≥ 3cm, lymph node metastasis, and TNM stage Ⅲ+Ⅳ laryngeal cancer α The expression was significantly higher in patients with medium to high differentiation, maximum tumor diameter<3cm, no lymph node metastasis, and TNM stage Ⅰ+Ⅱ(t/P=5.385/<0.001, 11.480/<0.001, 12.796/<0.001, 7.562/<0.001, 10.068/<0.001, 10.776/<0.001, 13.340/<0.001, 9.769/<0.001); MiR-552, HSP90 α The AUC for predicting the mortality efficacy of laryngeal cancer patients with binomial combination was 0.812, 0.806, and 0.925, respectively. The AUC for binomial combination was the highest(Z/P=4.218/0.009, 4.416/0.007). Multivariate logistic regression analysis showed that miR-552 ≥ 1.7 and HSP90 α≥ 0.8, poorly differentiated tumor, maximum tumor diameter ≥ 3cm, presence of lymph node metastasis, TNM stage Ⅲ+IV are independent risk factors for laryngeal cancer death [OR(95%CI)=2.557(1.027-5.182), 3.068(1.161-6.377), 1.962(1.035-5.729), 2.155(1.411-4.856), 3.442(1.306-5.713), 3.593(1.149-6.315)]. 64 patients in the LGC group died and 23 survived at the follow-up endpoint. MiR-552 ≥ 1.7 and HSP90 α≥ The median survival time of 0.8 laryngeal cancer patients is(31.6±5.4) months, shorter than miR-552<1.7 and HSP90 α< 0.8) Patient's(38.3±6.1) months(Log rank=7.412, P=0.003). Conclusions Laryngeal cancer patients miR-552 and HSP90 α The significantly increased expression is closely related to clinical pathological factors and prognosis, and can be used as a marker for evaluating the condition and prognosis of laryngeal cancer.

Objective To investigate the relationship between the expression of neuroregulatory protein 1(NRG1) and human epidermal growth factor receptor 3(HER3) in prostate cancer(PC) tissue and their clinical pathological characteristics and prognosis.Method Ninety-six PC patients diagnosed and treated in the urology department of Jilin Provincial People's Hospital from February 2015 to February 2020 were selected, and the expression of NRG1 and HER3 in the tissues was detected by immunohistochemistry; Kaplan Meier curve(Log Rank test) was used to compare the impact of different NRG1 and HER3 expressions on the prognosis of PC patients; COX regression analysis of prognostic factors in PC patients. Results The positive rates of NRG1 and HER3 in PC cancer tissues were 78.13%(75/96) and 75.00%(72/96), respectively, which were higher than those in adjacent tissues by 6.25%(6/96) and 8.33%(8/96)(χ2/P=101.670/<0.001, 87.771/<0.001). tnm="" stage="" gleason="" score="">7, and preoperative PSA level ≥ 20 μ The positive rates of NRG1 and HER3 in cancer tissues of g/L patients were higher than those in TNM staging stages Ⅰ-Ⅱ, Gleason score ≤7, and preoperative PSA level<20 μ G/L(χ2/P=6.181/0.013,8.533/0.003; 7.731/0.005,6.769/0.009; 6.508/0.011,7.376/0.007). The 3-year cumulative progression free survival rates of the NRG1 positive group and HER3 positive group were lower than those of the NRG1 negative group and HER3 negative group, respectively(χ2/P=4.267/0.039, 5.499/0.019). TNM stage Ⅲ, Gleason score>7, preoperative PSA ≥ 20 μ G/L, NRG1 positivity, and HER3 positivity are independent risk factors affecting the prognosis of PC patients [OR(95%CI)=1.448(1.118-1.875), 1.401(1.138-1.724), 1.353(1.059-1.728), 1.338(1.057-1.692), 1.293(1.014-1.649)].Conclusion The increased expression of NRG1 and HER3 in PC cancer tissue is associated with adverse clinical and pathological features of PC, and is a new tumor marker for evaluating the prognosis of PC.